NSTM · NovelStem International Corp.
$0.01
At close · Aug 31
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$493,324
Shares
49.33M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$616.34K
-42.3%
FY2012
Net Income
$2.38M
+173.6%
FY2025
Operating Margin
-925.21%
-380.9pp
FY2012
Diluted EPS
$0.05
+171.4%
FY2025
Operating Cash Flow
-$167.63K
+38.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| $510.7K | — | — | — | — | — | $616.34K | $1.07M | $4M | $4.52M | |
| $120.11K | $238.76K | $880.95K | $665.28K | $744.43K | $495.54K | — | — | — | — | |
| $3.59M | — | — | — | — | — | $2.85M | $2.78M | $3.68M | $4.34M | |
| — | — | — | — | — | — | $8433 | $15.73K | — | — | |
| $82.31K | — | — | — | — | — | $136.44K | $203.23K | $541.33K | $744K | |
| $120.11K | $238.76K | $939.92K | $3.54M | $434.43K | $495.54K | — | — | — | — | |
| $6.51M | — | — | — | — | — | $6.32M | $6.88M | $11.66M | $12.53M | |
| -$120.11K | -$238.76K | -$927.92K | -$3.53M | -$422.43K | -$495.54K | -$5.7M | -$5.81M | -$7.66M | -$8.01M | |
| — | — | — | — | — | — | -925.21% | -544.28% | -191.83% | -177.21% | |
| -$5.92M | — | — | — | — | — | -$5.57M | -$5.61M | -$7.12M | -$7.26M | |
| $50.86K | $36K | $425.42K | $99.02K | $11.02K | $6825 | — | — | — | — | |
| -$193.19K | $2.61M | -$515.42K | -$359.02K | -$11.02K | — | $2.07M | $2.03M | $6311 | -$35.23K | |
| — | $640 | -$161.05K | -$338.62K | -$719.8K | -$843.27K | -$142K | $593.77K | $765.02K | -$2.99M | |
| -$313.29K | $2.37M | -$1.44M | -$3.88M | -$433.45K | -$502.36K | -$4.41M | -$6.94M | — | — | |
| — | — | — | — | — | — | -$5.82M | $130.57K | $283.76K | -$83.29K | |
| -$307.56K | $2.38M | -$3.23M | -$4.19M | -$765.73K | -$1.35M | $10.41M | -$6.86M | $4.91M | -$5.62M | |
| — | — | — | — | — | — | 1688.94% | -642.72% | 122.79% | -124.39% | |
| — | — | — | — | — | — | — | $85.09K | -$49.92K | -$2409 | |
| -$300.17K | $2.39M | -$3.23M | — | — | — | — | — | — | — | |
| USD/shares | — | $0.05 | -$0.07 | -$0.09 | -$0.02 | -$0.03 | — | — | — | — |
| USD/shares | — | $0.05 | -$0.07 | -$0.09 | -$0.02 | — | — | — | — | — |
| shares | — | 46.88M | 46.88M | 46.88M | 46.88M | 44.26M | 23.18M | 24.38M | — | — |
| shares | — | 47.8M | 46.88M | 46.88M | 46.88M | 44.26M | 23.18M | 24.38M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 5.41×
EV/EBIT
—
Diagnostics & Research median 33.46×
P/E (TTM)
—
Diagnostics & Research median 33.47×